ライフサイエンスコーパス: antihypertensive therapy

1 se these drugs in patients already receiving antihypertensive therapy.

2 atient was discharged with anticoagulant and antihypertensive therapy.

3 equired further intensification of discharge antihypertensive therapy.

4 RDN emerged as an innovative interventional antihypertensive therapy.

5 or antagonist, or AngII infusion with triple-antihypertensive therapy.

6 mm Hg diastolic and treated with intravenous antihypertensive therapy.

7 bo required the initiation of or a change in antihypertensive therapy.

8 t is resistant to most forms of conventional antihypertensive therapy.

9 t the study, most were on antithrombotic and antihypertensive therapy.

10 the score components of diabetes and use of antihypertensive therapy.

11 ssociated with nonadherence to statin and/or antihypertensive therapy.

12 ossibility of targeting the EP1 receptor for antihypertensive therapy.

13 e provider in improving patient adherence to antihypertensive therapy.

14 ians than in African Americans regardless of antihypertensive therapy.

15 he physiologic evidence of renoprotection by antihypertensive therapy.

16 cal cardiovascular disease and not receiving antihypertensive therapy.

17 pine, or placebo in addition to conventional antihypertensive therapy.

18 sease and should be preferred for first-line antihypertensive therapy.

19 kers, should no longer be used as first-line antihypertensive therapy.

20 on who were under evaluation for a change in antihypertensive therapy.

21 disease and those receiving anticoagulant or antihypertensive therapy.

22 those adherent to statin, but nonadherent to antihypertensive, therapy.

23 rovide a potential target for individualized antihypertensive therapies.

24 wer risk of combined MI or stroke than other antihypertensive therapies.

25 59) for those nonadherent both to statin and antihypertensive therapy, 1.82 (95% CI: 1.43 to 2.33) fo

26 nsmitted BP data to pharmacists who adjusted antihypertensive therapy accordingly.

27 tions between 1953 and 1957 and were free of antihypertensive therapy and cardiovascular disease.

28 More experience is being gained with antihypertensive therapy and expectant management in sev

29 ians at all exercise workloads regardless of antihypertensive therapy and had over a 90% higher likel

30 and of all-cause mortality in the setting of antihypertensive therapy and regression of ECG left vent

31 ith statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatm

32 those non-adherent to statin but adherent to antihypertensive therapy, and 1.30 (95% CI: 0.53 to 3.20

33 ead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk re

34 Aspirin, lipid-lowering or antihypertensive therapy, and interim revascularization

35 ramework for addressing patient adherence to antihypertensive therapy, and to propose future directio

36 ust, 2010, for randomised clinical trials of antihypertensive therapy (ARBs, angiotensin-converting-e

37 Recent developments concerning pediatric antihypertensive therapy are considered, as well as new

38 d ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation

39 d ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation

40 multivariable models adjusting for age, sex, antihypertensive therapy, body mass index, heart rate, t

41 nzyme (ACE) inhibitors are used primarily in antihypertensive therapy but also are known to improve w

42 The probability of stopping antihypertensive therapy decreased as compared with the

43 terol, estimated glomerular filtration rate, antihypertensive therapy, diabetes mellitus, and smoking

44 sence of renal failure, and documentation of antihypertensive therapy, diabetic status, proteinuria s

45 further reducing the diastolic pressure with antihypertensive therapy, especially in patients with co

46 Antihypertensive therapy, especially with inhibitors of

47 lyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was admin

48 lyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was admin

49 No objective analysis of advertising for antihypertensive therapies exists, however.

50 Large-scale trials to assess the value of antihypertensive therapy for older patients with SBP of

51 te, free of coronary heart disease (CHD) and antihypertensive therapy, from the Chicago Heart Associa

52 The hemodynamics of hypertension and antihypertensive therapy have generally been approached

53 hough black patients received more intensive antihypertensive therapy, Hispanics were undertreated.

54 the pathophysiology, risks, and benefits of antihypertensive therapies in the patient with intracran

55 is the optimal target for BP lowering during antihypertensive therapy in adults?

56 aptured year-by-year adherence to statin and antihypertensive therapy in both study groups and estima

57 e endothelial, cardiac, and renal effects of antihypertensive therapy in hypertension and may explain

58 hypotension; the effectiveness of nocturnal antihypertensive therapy in patients with coexistent neu

59 cal trials from 1965 through October 2010 of antihypertensive therapy in patients with type 2 diabete

60 on, it is important to highlight the role of antihypertensive therapy in primary prevention.

61 t failure (CHF) in the setting of aggressive antihypertensive therapy in unclear.

62 Antihypertensive therapy included angiotensin-converting

63 aracteristics associated with an increase in antihypertensive therapy included increased levels of bo

64 nell product electrocardiographic LVH during antihypertensive therapy is associated with a lower like

65 nell product electrocardiographic LVH during antihypertensive therapy is associated with fewer hospit

66 uct and Sokolow-Lyon voltage criteria during antihypertensive therapy is associated with lower likeli

67 Because antihypertensive therapy is effective in elderly patient

68 ough literature on reduction of LV mass with antihypertensive therapy is extensive, little informatio

69 versus development of new ECG strain during antihypertensive therapy is unclear.

70 re have been advances in management, such as antihypertensive therapy, magnesium sulphate, and fluid

71 Different antihypertensive therapies may vary in their effect on L

72 blind candesartan or placebo with open-label antihypertensive therapy (mostly thiazide diuretics) add

73 Selection of appropriate antihypertensive therapy necessitates the careful consid

74 eeclampsia and to assess the action of other antihypertensive therapies on rcSO2.

75 f incident dementia; however, the effects of antihypertensive therapy on cognitive function in contro

76 The long-term effect of chronic antihypertensive therapy on growth, as well as the preve

77 combined outcome of MI and stroke than other antihypertensive therapies (OR, 0.49; 95% CI, 0.32-0.77)

78 diabetes mellitus, systolic blood pressure, antihypertensive therapy, prior coronary disease, and le

79 hest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo a

80 Antihypertensive therapy reduces the risk of cardiovascu

81 with hypertension who were not receiving any antihypertensive therapy (relative hazard, 0.91; 95 perc

82 of electrocardiographic LVH criteria during antihypertensive therapy remains unclear.

83 baseline severity of ECG LVH, losartan-based antihypertensive therapy resulted in greater regression

84 High adherence to antihypertensive therapy results in a significant reduct

85 sis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reduc

86 Antihypertensive therapy should be adjusted according to

87 Barbiturates offer an alternative antihypertensive therapy since they decrease blood press

88 These findings suggest that antihypertensive therapy targeted at regression or preve

89 Antihypertensive therapy targeted at regression or preve

90 ave less regression of CP LVH in response to antihypertensive therapy than patients without diabetes,

91 Antihypertensive therapy that did not include renin-angi

92 Despite the marked changes in antihypertensive therapy that had occurred, BP remained

93 relative to those who adhered to statins and antihypertensive therapy, the odds ratio at the year of

94 or age, sex, systolic blood pressure, use of antihypertensive therapy, total and high-density lipopro

95 tics will rightfully remain a cornerstone in antihypertensive therapy, we should remember (as we were

96 major changes in the clinical guidelines for antihypertensive therapy were introduced.

97 Renal dysfunction and the need for antihypertensive therapy were much the same in both grou

98 atory data, as well as immunosuppressive and antihypertensive therapy were recorded.

99 derate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting

100 nsion (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine

101 HEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepp

102 However, participants receiving antihypertensive therapy (with blood pressure controlled

103 partitioning to assess the probability that antihypertensive therapy would be increased at a given c